Fulcrum Therapeutics (United States)
company in Cambridge, United States
FULC Nasdaq
SEC CIK 1680581
Follow Fulcrum Therapeutics (United States)
Weekly email: filings, results
Net income
−$10.9M
+44.2% vs same quarter last year
EPS, diluted
−$0.14
+54.8% vs same quarter last year
Operating cash flow
−$13.4M
+5.7% vs same quarter last year
Operating income
−$13.9M
+36.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$74.9M |
| FY24 | $80M | −$9.7M |
| FY23 | $2.8M | −$97.3M |
| FY22 | $6.3M | −$109.9M |
| FY21 | $19.2M | −$80.8M |
| FY20 | $8.8M | −$70.8M |
| FY19 | - | −$82.7M |
| FY18 | - | −$32.6M |
| FY17 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | −27.4% | −12.2% |
| FY23 | −3945.2% | −3470.2% |
| FY22 | −1774.9% | −1732.4% |
| FY21 | −423% | −421.9% |
| FY20 | −811.6% | −802.7% |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$60.4M |
| FY24 | −$2.5M |
| FY23 | −$91.5M |
| FY22 | −$99M |
| FY21 | −$80.2M |
| FY20 | −$55M |
| FY19 | −$40.3M |
| FY18 | −$31.5M |
| FY17 | - |
- Fulcrum Therapeutics (United States)
- Healthcare median
Show the numbers
| Year | Fulcrum Therapeutics (United States) | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | −12.2% | −47% |
| FY23 | −3470.2% | −58% |
| FY22 | −1732.4% | −80.4% |
| FY21 | −421.9% | −71.8% |
| FY20 | −802.7% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |